OncLive SOSS

ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 7

Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

January 27, 2025

Carsten Niemann, MD, PhD, Arnon Kater, MD, PhD, Othman Al-Sawaf, MD, John F. Seymour, MBBS, FRACP, PhD

Panelists discuss the role of ven-ibr in patient populations.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Recent Guideline Updates in the Frontline Management of CLL

EP. 2: Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

EP. 3: Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

EP. 4: Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

EP. 5: Clinical Insights and Real-World Evidence

EP. 6: Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

EP. 7: Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

EP. 8: Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

EP. 9: Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy

EP. 10: Relapse After Venetoclax-Based Therapy: Early vs Late Management

EP. 11: Progression on BTK Inhibitors: Treatment Options and Considerations

EP. 12: Emerging Agents and Future Strategies in Relapsed/Refractory CLL

EP. 13: Reflections and Future Directions in CLL Management

Video content above is prompted by the following:

What is role of ven-ibr in these patient populations?
When may you opt for this approach over other time-limited therapy options (ven-obi) or continuous BTKi therapy?

x